Achieved 6% revenue growth and 7% adjusted net income growth, with double-digit EPS growth in a challenging macro environment.
2026 guidance set at 3%-5% revenue growth and 3%-6% adjusted net income growth, reflecting prudent expectations amid competition and market dynamics.
Margin expansion expected to continue, though at a slower pace due to lower top-line growth and ongoing investments.
Guidance incorporates 2-3 points of price increases and considers competitive pressures on key products.
Mix of livestock and companion animal businesses factored into margin and growth outlook for 2026.
Transitioning to a synchronized calendar year reporting for both U.S. and international operations starting Q1 2026.
Historical reporting used a one-month lag for international; 2026 guidance remains on the legacy basis until the change.
Recasted financials for 2024 and 2025 will be provided to ensure comparability.
No impact of a 13-month year or 4-month quarter; all periods will remain 12 months.
Operational changes, such as timing of price increases, have been made to align with the new calendar.
Confident in portfolio differentiation, especially in dermatology with products like Apoquel (film-coated and chewable) and Cytopoint.
Recent competitor launches, such as Merck’s NUMELVI, were anticipated and factored into guidance.
Market for dermatology products remains expandable, with high satisfaction and compliance rates supporting continued growth.
Simparica franchise expected to lead growth, followed by KeyDerm and pain franchises.
Pricing strategy remains value-driven, with fine-tuning based on market and product dynamics.
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Search for any keyword across all transcripts simultaneously.
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
The easiest way to stay updated during earnings season.
All events from public companies. Live and recorded.
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
)
)
Zoetis Inc. is an American drug manufacturer that produces and sells medicine, medications, and vaccinations for both pets and livestock. The company is one of the largest in the industry, and its product range includes treatments for a variety of animal health issues, from common ailments in domestic pets to disease prevention in livestock. Zoetis is active in over 100 countries worldwide and has a dominating presence in the American animal health sector. The company is headquartered in Parsippany, New Jersey, and its shares are listed on the NYSE.
Zoetis was founded in 1952 as a subsidiary of Pfizer and marked the beginning of the pharmaceutical company’s agricultural division. Over the years, the division evolved, focusing on the development and marketing of vaccines, medicines, and other products for animals. The division grew to become one of the largest players in the industry, and its parent company decided it was best to go separate ways from the company, for Pfizer to focus on its business while allowing Zoetis to continue with what it did best. Said and done, and in 2013 Pfizer spun off the division and Zoetis became its own company. Today, it competes against names such as Elanco and Virbac in the animal health industry.
The company’s portfolio includes vaccines, medicines, diagnostics, and genetic tests, catering to both livestock and companion animals. These products aim to prevent, treat, and control diseases, ensuring owners can provide the best possible healthcare possible for their animals. In the livestock sector, Zoetis provides medications and vaccines for cattle, swine, poultry, and sheep, with its products focusing on ensuring that the animals are healthy and productive. For companion animals, Zoetis offers vaccines, dermatology products, anti-infectives, and products for pain and management.
Zoetis provides a comprehensive range of products and services specifically designed for veterinarians. Beyond pharmaceuticals, which are prescribed and oftentimes administered by veterinarians, Zoetis offers diagnostic tools and tests. Moreover, Zoetis provides digital tools such as practice management software, helping veterinarians keep track of their operations and journals.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Explore our global coverage